Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K A Stringer

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Pharmacotherapy|December 28, 1999
Emergence of low-molecular-weight heparins in cardiologyK A Stringer
The Annals of Pharmacotherapy|June 1, 1994
Beyond thrombolysis: other effects of thrombolytic drugsK A Stringer
The Journal of Practical Nursing|June 1, 1991
Update on risk factors for coronary heart diseaseK A Stringer
Pharmacotherapy|April 20, 2000
Tissue plasminogen activator inhibits reactive oxygen species production by macrophagesK A Stringer
Pharmacotherapy|September 1, 1996
Biochemical and pharmacologic comparison of thrombolytic agentsK A Stringer
Pharmacotherapy|August 6, 1998
TIMI grade flow, mortality, and the GUSTO-III trialK A Stringer
The Annals of Pharmacotherapy|July 20, 1999
The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromesK A Stringer
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 16, 1997
Clinical trials in thrombolytic therapy, Part 1: Outcome markers that go beyond mortality reductionK A Stringer
Pharmacotherapy|November 5, 1997
Validity of the GUSTO trial's main conclusion--author's reply. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded CoronariesK A Stringer
The Annals of Pharmacotherapy|December 1, 1992
Hirudins: antithrombin anticoagulantsK A Stringer, J Lindenfeld
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Pharmacotherapy|December 28, 1999
Emergence of low-molecular-weight heparins in cardiologyK A Stringer
The Annals of Pharmacotherapy|June 1, 1994
Beyond thrombolysis: other effects of thrombolytic drugsK A Stringer
The Journal of Practical Nursing|June 1, 1991
Update on risk factors for coronary heart diseaseK A Stringer
Pharmacotherapy|April 20, 2000
Tissue plasminogen activator inhibits reactive oxygen species production by macrophagesK A Stringer
Pharmacotherapy|September 1, 1996
Biochemical and pharmacologic comparison of thrombolytic agentsK A Stringer
Pharmacotherapy|August 6, 1998
TIMI grade flow, mortality, and the GUSTO-III trialK A Stringer
The Annals of Pharmacotherapy|July 20, 1999
The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromesK A Stringer
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 16, 1997
Clinical trials in thrombolytic therapy, Part 1: Outcome markers that go beyond mortality reductionK A Stringer
Pharmacotherapy|November 5, 1997
Validity of the GUSTO trial's main conclusion--author's reply. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded CoronariesK A Stringer
The Annals of Pharmacotherapy|December 1, 1992
Hirudins: antithrombin anticoagulantsK A Stringer, J Lindenfeld
Pageof 4